- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
A means of improving cerebral circulation and brain metabolism. Inhibits phosphodiesterase activity, which contributes to the accumulation of cAMP in tissues. It has a vasodilating effect mainly on the vessels of the brain, which is caused by direct myotropic antispasmodic action. Systemic blood pressure drops slightly. It improves blood flow and microcirculation in the brain tissues, reduces platelet aggregation, and contributes to the normalization of the rheological properties of blood. It improves the portability of hypoxia by brain cells, facilitating the transport of oxygen to tissues due to a decrease in the red blood cell affinity for it, enhancing the absorption and metabolism of glucose. Increases the content of catecholamines in brain tissue.
Acute and chronic cerebrovascular insufficiency. Dyscirculatory encephalopathy, accompanied by memory impairment, dizziness, headache. Posttraumatic encephalopathy. Vascular diseases of the retina and choroid. Hearing impairment of vascular or toxic origin, Meniere's disease, dizziness of labyrinth origin. Vegetative-vascular dystonia in climacteric syndrome.
1 tab .:
Vinpocetine 5 mg
Excipients: potato starch - 64.3 mg, lactose monohydrate (milk sugar) - 171.9 mg, colloidal silicon dioxide (aerosil) - 1.7 mg, talc - 4.7 mg, magnesium stearate - 2.4 mg.
Vinpocetine is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Cavinton Comforte||Gedeon Richter||Hungary||pills|
|Cavinton Forte||Gedeon Richter||Hungary||pills|
No customer reviews for the moment.
Dosage and Administration
Maverex administered in / in (strictly), in the form of a 15-20 minute infusion. It is used both as a monotherapy and in combination with other antitumor agents. When choosing a dose and mode of administration in each individual case, refer to the special literature.
In monotherapy mode, the usual dose of Maverex is 25-30 mg / m2 of body surface once a week. The drug is diluted in 0.9% solution of sodium chloride or 5% dextrose solution to a concentration of 1.5-3.0 mg / ml. After the introduction of the drug, the vein should be washed by entering an additional 50-100 ml of 0.9% sodium chloride solution.
From the side of blood-forming organs: granulocytopenia, anemia; rarely - thrombocytopenia.
The smallest number of granulocytes is observed on days 7-10 from the start of therapy, recovery occurs in the next 7-14 days.
On the part of the nervous system: a decrease or loss of deep tendon reflexes, paresthesia, hyperesthesia, weakness in the legs, pain in the jaw, headache, intestinal paresis; rarely paralytic bowel obstruction.
On the part of the digestive system: nausea, vomiting, anorexia, constipation, diarrhea, dysphagia, mucositis, pancreatitis, increased bilirubin levels and increased activity of hepatic transaminases.
On the part of the respiratory system: difficulty breathing, shortness of breath, bronchospasm, interstitial pneumonia, acute respiratory distress syndrome.
Since the cardiovascular system: chest pain, increase or decrease in blood pressure, tachycardia; rarely - myocardial infarction, pulmonary edema.
Local reactions: pain or redness at the injection site; with extravasation - cellulite, phlebitis and, possibly, necrosis of the surrounding tissues.
Others: weakness, alopecia, myalgia, arthralgia, skin rashes, allergic reactions, flushes of heat to the face, increased creatinine levels, hyponatremia, hemorrhagic cystitis and syndrome of inappropriate antidiuretic hormone secretion.
- Hypersensitivity to vinka alkaloids;
- severe liver dysfunction;
- baseline neutrophil count
- radiation therapy of the hepatobiliary area;
- breastfeeding period.
- respiratory failure;
- oppression of bone marrow hematopoiesis (including after previous chemotherapy or radiation treatment);
- constipation or a history of intestinal obstruction in history;
- history of neuropathy.
- Brand name: Vinelbin
- Active ingredient: Vinorelbine
- Dosage form: Concentrate for solution for infusion
- Manufacturer: Fresenius Kabi
- Country of Origin: Germany
- Capillary electrophoresis separation of vinpocetine and related compounds: Prediction of electrophoretic mobilities in partly aqueous media
- Effects of vinpocetine in scopolamine-induced learning and memory impairments
- General neuropharmacology of vinpocetine: A putative cerebral activator
- Possible memory-enhancing properties of vinpocetine
- Correlation between cerebral circulation and intellectual impairment in patients with “aging brain,” and the effect of vinpocetine on cerebral circulation
- Restoration of microsieve filterability of human red cells after exposure to hyperosmolarity and lactacidosis: Effect of vinpocetine
- Computed tomography study of cerebral infarctions treated with vinpocetine
- Placebo-controlled, double-blind, crossover study to investigate the hypoxia-protective effect of vinpocetine by psychophysiological methodology in healthy volunteers
- On the possible role of central monoaminergic systems in the central nervous system actions of vinpocetine
- Effect of vinpocetine on monoamine receptor binding and synaptosomal uptake in the rat brain
- Vinpocetine facilitates noradrenaline release in rat brain cortex slices
- Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia
- Electrophysiologic effects of vinpocetine and vincamine on isolated rabbit papillary muscle in normal- and low-potassium medium
- Effect of vinpocetine on age-related differences in brain function of aged fischer rats
- Effect of vinpocetine on the sleep-wake cycle of rats
- Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats
- Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory
- Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome
- Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine
- Multidisciplinary approach on characterizing a mechanochemically activated composite of vinpocetine and crospovidone
- Kinetics and mechanisms of vinpocetine degradation in aqueous solutions
- Quantitative determination of vinpocetine in human plasma by capillary gas chromatography—mass spectrometry
- Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo
- Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion